Influence of P-glycoprotein modulation on plasma concentrations and pharmacokinetics of orally administered prednisolone in dogs

American Journal of Veterinary Research

Volumn 73, Issue 6, 2012, Pages 900-907

  van der Heyden Dr , Sara ^a   Croubels, Siska ^a   Gadeyne, Caroline ^a   Ducatelle, Richard ^a   Daminet, Sylvie ^a   Escobar, Hugo Murua ^b   Sterenczak, Katharina ^b   Polis, Ingeborgh ^a   Schauvliege, Stijn ^a   Hesta, Myriam ^a   Chiers, Koen ^a  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; KETOCONAZOLE; MESSENGER RNA; PREDNISOLONE; RIFAMPICIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COLON BIOPSY; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DUODENUM BIOPSY; ENDOSCOPY; EXPERIMENTAL DOG; FECES; FEMALE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MALE; MODULATION; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; UPREGULATION;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; AREA UNDER CURVE; BIOPSY; CHROMATOGRAPHY, LIQUID; DOGS; GENE EXPRESSION REGULATION; KETOCONAZOLE; P-GLYCOPROTEIN; PREDNISOLONE; REAL-TIME POLYMERASE CHAIN REACTION; RIFAMPIN; TANDEM MASS SPECTROMETRY;

ANIMALIA; CANIS FAMILIARIS;

EID: 84861556718     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.73.6.900     Document Type: Article

References (49)

1. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129-134.
2. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55:3-29.
3. Sparreboom A, Van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997;94:2031-2035.
4. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42:59-98.
5. Napoli KL, Wang ME, Stepkowski SM, et al. Relative tissue distributions of cyclosporin and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions. Ther Drug Monit 1998;20:123-133.
6. Aungst BJ. P-glycoprotein secretory transport and other barriers to the oral delivery of anti-HIV drugs. Adv Drug Deliv Rev 1999;39:105-116.
7. Suzuki H, Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 2000;12:3-12.
8. Martinez M, Modric S, Sharkey M, et al. The pharmacogenomics of P-glycoprotein and its role in veterinary medicine. J Vet Pharmacol Ther 2008;31:285-300.
9. McEntee M, Silverman JA, Rassnick K, et al. Enhanced bioavailability of oral docetaxel by co-administration of cyclopsorin A in dogs and rats. Vet Comp Oncol 2003;2:105-112.
10. Amatori FM, Meucci V, Giusiani M, et al. Effect of grape fruit juice on the pharmacokinetics of cyclosporine in dogs. Vet Rec 2004;164:180-181.
11. Dahlinger J, Gregory C, Bea J. Effect of ketoconazole on cyclosporine dose in healthy dogs. Vet Surg 1998;27:64-68.
12. Craven M, Simpson JW, Ridyard AE, et al. Canine inflammatory bowel disease: retrospective analysis of diagnosis and outcome in 8 cases (1995-2002). J Small Anim Pract 2004;45:336-342.
13. Fujino Y, Sawamura S, Kurakawa N, et al. Treatment of chronic lymphocytic leukemia in three dogs with melpahalan and prednisolone. J Small Anim Pract 2004;45:298-303.
14. Batchelor DJ, Bright SR, Ibarrola P, et al. Long-term survival after combination chemotherapy for bilateral renal malignant lymphoma in a dog. N Z Vet J 2006;54:147-150.
15. Simon D, Nolte I, Eberle N, et al. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J Vet Intern Med 2006;20:948-954.
16. Borst P, Oude Elferink R. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-592.
17. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-398.
18. Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999;1461:237-267.
19. Association of Official Analytical Chemists. Official methods of analysis. 14th ed. Washington, DC: Association of Official Analytical Chemists, 1984.
20. Mason V. Some observations on the distribution and origin of nitrogen in sheep faeces. J Agric Sci 1969;73: 99-111.
21. Hesta M, Roosen W, Janssens GPJ, et al. Prebiotics affect nutrient digestibility but not faecal ammonia in dogs fed increased dietary protein levels. Br J Nutr 2003;90:1007-1014.
22. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987;84:7735-7738.
23. Karssen AM, Meijer OC, van der Sandt ICJ, et al. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol 2002;175:251-260.
24. Yates CR, Chang C, Kearbey JD, et al. Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res 2003;20:1794-1803.
25. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104:147-153.
26. Larsen UL, Hyldahl Olesen L, Guldborg Nyvold C, et al. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest 2007;67:123-134.
27. Oswald S, Haenisch S, Fricke C, et al. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 2006;79:206-217.
28. Wang EJ, Lew K, Casciano CN, et al. Interaction of common azole antifungals with P-glycoprotein. Antimicrob Agents Chemother 2002;46:160-165.
29. Taub ME, Podila L, Ely D, et al. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos 2005;33:1679-1687.
30. Hugnet C, Lespine A, Alvinerie M. Multiple oral dosing of ketoconazole increases dog exposure to ivermectin. J Pharmaceut Sci 2007;10:311-318.
31. Coelho JC, Tucker R, Mattoon J, et al. Biliary excretion of technetium-99-sestamibi in wild-type dogs and in dogs with intrinsic (ABCB1-1Δ mutation) and extrinsic (ketoconazole treated) P-glycoprotein deficiency. J Vet Pharmacol Ther 2009;32:417-421.
32. Venkatakrishnan K, von Moltke L, Greenblatt D. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmakokinet 2000;38:111-180.
33. Kovarik JM, Beyer D, Bizot MN, et al. Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 2005;45:514-518.
34. Ridtitid W, Wongnawa M, Mahatthanatrakul W, et al. Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers. J Clin Pharm Ther 2005;30:285-290.
35. Grimm SW, Richtand NM, Winter HR, et al. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006;61:58-69.
36. O'Neill T, Edwards GA, Holloway S. Efficacy of combined cyclosporine A and ketoconazole treatment of anal furunculosis. J Small Anim Pract 2004;45:239-243.
37. Myre SA, Schoeder TJ, Grund VR, et al. Critical ketoconazole dosage range for cyclosporine clearance inhibition in the dog. Pharmacology 1991;43:233-241.
38. Kuroha M, Shirai Y, Shimoda M. Multiple oral dosing of ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in Beagle dogs. J Vet Pharmacol Ther 2004;27:355-359.
39. Mayer UK, Glos K, Schlmid M, et al. Adverse effects of ketoconazole in dogs-a retrospective study. Vet Dermatol 2008;19:199-208.
40. Mitchell E, Podila L, Ely D, et al. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos 2005;33:1679-1687.
41. Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002;300:1036-1045.
42. Katragada S, Budda B, Anand BS, et al. Role of efflux pumps and metabolising enzymes in drug delivery. Expert Opin Drug Deliv 2005;2:683-705.
43. Patel J, Mitra AK. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. Pharmacogenomics 2001;2:401-415.
44. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A an P-glycoprotein. Clin Pharm 2001;40:159-168.
45. Kyokawa Y, Nishibe Y, Wakabayashi M, et al. Induction of intestinal cytochrome P450 (CYP3A) by rifampicin in Beagle dogs. Chem Biol Interact 2001;134:291-305.
46. Pichard L, Fabre I, Daujat M, et al. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporine A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992;41:1047-1055.
47. Sergent T, Dupont I, Jassogne C, et al. CYP1A1 induction and CYP3A4 inhibition by the fungicide imazalil in the human intestinal Caco-2 cells-comparison with other conazole pesticides. Toxicol Lett 2009;184:159-168.
48. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006;23:4-33.
49. Lamba JK, Lamba V, Yasuda K, et al. Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. J Pharmacol Exp Ther 2004;311:811-821.